IBAI.LSE Imaging Biometrics Ltd.
- Market cap
- GBX 1.92M
- P/E
- -
- P/B
- 4.07x
- ROE
- 96.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is IBAI.LSE undervalued?
Graham numberThe Graham number of Imaging Biometrics Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Imaging Biometrics Ltd. fundamental analysis
No fundamental analysis for Imaging Biometrics Ltd. yet.
Imaging Biometrics Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Imaging Biometrics Ltd.
Imaging Biometrics Ltd. provides clinical treatments to patients in the field of medical imaging diagnostics in the United Kingdom, China, the European Union, South America, Australia, and the United States. It operates through Holding Company, Medical Software, Oral Gallium Maltolate (GaM), and Organ-on-a-Chip segments. The company develops ready-to-use software applications comprising IB Neuro, an MRI perfusion platform that generates quantitative relative cerebral blood v…
Full company profileImaging Biometrics Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Imaging Biometrics Ltd. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 165K | 273K | 255K | 521K | 536K | 609K | 750K | 788K | 1.67M |
| Gross Profit | - | - | 130K | 264K | 247K | 504K | 534K | 482K | 688K | 646K | 1.46M |
| Operating Income | -272K | -258K | -580K | -617K | -686K | -490K | -501K | -406K | -328K | -157K | 355K |
| EBITDA | - | -276.00 | -546K | -499K | -569K | -357K | -360K | -499K | -273K | -66.0K | 551K |
| Net Income | -303K | -281K | -764K | -639K | -718K | -501K | -512K | -624K | -327K | -401K | 295K |
| EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 80.0K | 693K | 1.02M | 1.87M | 1.43M | 1.58M | 1.27M | 721K | 930K | 1.01M | 1.18M |
| Total Liabilities | 427K | 103K | 255K | 209K | 362K | 393K | 561K | 626K | 627K | 779K | 875K |
| Shareholders' Equity | 28.0K | 590K | 763K | 1.66M | 1.07M | 1.19M | 707K | 94.9K | 303K | 235K | 308K |
| Cash & Short-term Investments | 66.0K | 387K | 28.8K | 866K | 479K | 729K | 314K | 139K | 53.5K | 113K | 49.4K |
| Total Debt | 375K | 4.00K | 62.9K | 58.0K | 93.3K | 55.4K | 62.2K | - | - | 172K | 177K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -256K | -211K | -684K | -525K | -423K | -289K | -375K | -96.8K | -136K | 74.3K | 39.4K |
| Capital Expenditure | 0.00 | 47.0K | 32.9K | 116K | 31.6K | 56.6K | 39.9K | 78.4K | 309K | 4.00 | 0.00 |
| Free Cash Flow | -256K | -258K | -717K | -641K | -455K | -345K | -415K | -175K | -136K | 74.3K | 39.4K |
| Ratios | |||||||||||
| ROE | -1,082.1% | -47.6% | -100.2% | -38.5% | -67.0% | -42.1% | -72.4% | -657.2% | -108.1% | -170.4% | 96.0% |
| ROA | -378.8% | -40.5% | -75.1% | -34.2% | -50.1% | -31.6% | -40.4% | -86.6% | -35.2% | -39.5% | 25.0% |
| Net Profit Margin | - | - | -463.2% | -234.1% | -281.0% | -96.2% | -95.5% | -102.4% | -43.6% | -50.9% | 17.7% |
| Debt to Equity | 13.39x | 0.01x | 0.08x | 0.03x | 0.09x | 0.05x | 0.09x | - | - | 0.73x | 0.58x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Imaging Biometrics Ltd. dividends
Imaging Biometrics Ltd. has not paid dividends in the last 9 fiscal years.
Who owns Imaging Biometrics Ltd.
- Insiders 5.65%
- Institutions 29.35%
- Public & others 65.00%
- Shares outstanding 247M
- Free float 236M
Imaging Biometrics Ltd. company profile
- Company name
- Imaging Biometrics Ltd.
- Ticker
- IBAI.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Information Services
- Employees
- 7
- Fiscal year end
- December
- Address
- IFC5, Saint Helier, Jersey, JE1 1ST
- Website
- imagingbiometrics.com
About Imaging Biometrics Ltd.
Imaging Biometrics Ltd. provides clinical treatments to patients in the field of medical imaging diagnostics in the United Kingdom, China, the European Union, South America, Australia, and the United States. It operates through Holding Company, Medical Software, Oral Gallium Maltolate (GaM), and Organ-on-a-Chip segments. The company develops ready-to-use software applications comprising IB Neuro, an MRI perfusion platform that generates quantitative relative cerebral blood volume maps; IB Delta T1 maps, an image processing tool kit containing fundamental capabilities designed for routine use in medical imaging; IB Clinic platforms; and QSMetric, a quantitative susceptibility mapping solution. It also provides IB Nimble for collaborative discussions for any complex disease or emergent healthcare setting; IB Rad Tech, which automates and simplifies complex imaging tasks; IB Diffusion, which analyzes MR diffusion-weighted images; and IB DCE, which analyzes dynamic contrast-enhanced MRI images. In addition, the company offers IB arterial spin labeling (ASL), a software solution that enables non-invasive, quantitative measurement of cerebral blood flow using MRI; Liver Surface Nodularity (LSN), an imaging tool designed to non-invasively assess chronic liver disease using commonly acquired CT images; and StoneChecker, a medical software tool designed to aid clinical decision making by providing information about a patient's kidney stone. Further, it provides fractional tumor burden (FTB) maps, a quantitative perfusion-based biomarker that distinguishes high-grade brain tumor from non-tumor on a voxel-wise basis; and Quasi Vivo, an organ-on-a-chip platform. Additionally, the company develops oral GaM, which has completed a Phase 1 clinical trial for the treatment of glioblastoma. The company was formerly known as IQ-AI Limited and changed its name to Imaging Biometrics Ltd. in May 2025. Imaging Biometrics Ltd. was incorporated in 1965 and is based in Saint Helier, Jersey.
Imaging Biometrics Ltd. management
2- Mr. Trevor Edward Brown M.B.A.CEO & Director · born 1946
- Mr. David W. J. SmithChief Operating Officer